Background: Bile acids (BAs) have attracted attention in the research of irritable bowel syndrome with predominant diarrhea (IBS-D) due to their ability to modulate bowel function and their tight connection with the gut microbiota. The composition of the fecal BA pool in IBS-D patients is reportedly different from that in healthy populations. We hypothesized that BAs may participate in the pathogenesis of IBS-D and the altered BA profile may be correlated with the gut microbiome.
Aim: To investigate the role of BAs in the pathogenesis of IBS-D and the correlation between fecal BAs and gut microbiota.
Methods: Fifty-five IBS-D patients diagnosed according to the Rome IV criteria and twenty-eight age-, sex-, and body mass index-matched healthy controls (HCs) were enrolled in this study at the gastroenterology department of China-Japan Friendship Hospital. First, clinical manifestations were assessed with standardized questionnaires, and visceral sensitivity was evaluated the rectal distension test using a high-resolution manometry system. Fecal primary BAs including cholic acid (CA) and chenodeoxycholic acid (CDCA), secondary BAs including deoxycholic acid (DCA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) as well as the corresponding tauro- and glyco-BAs were examined by ultraperformance liquid chromatography coupled to tandem mass spectrometry. The gut microbiota was analyzed using 16S rRNA gene sequencing. Correlations between fecal BAs with clinical features and gut microbiota were explored.
Results: Fecal CA (IBS-D: 3037.66 [282.82, 6917.47] nmol/g, HC: 20.19 [5.03, 1304.28] nmol/g; < 0.001) and CDCA (IBS-D: 1721.86 [352.80, 2613.83] nmol/g, HC: 57.16 [13.76, 1639.92] nmol/g; < 0.001) were significantly increased, while LCA (IBS-D: 1621.65 [58.99, 2396.49] nmol/g, HC: 2339.24 [1737.09, 2782.40]; = 0.002] and UDCA (IBS-D: 8.92 [2.33, 23.93] nmol/g, HC: 17.21 [8.76, 33.48] nmol/g; = 0.025) were significantly decreased in IBS-D patients compared to HCs. Defecation frequency was positively associated with CA ( = 0.294, = 0.030) and CDCA ( = 0.290, = 0.032) and negatively associated with DCA ( = -0.332, = 0.013) and LCA ( = -0.326, = 0.015) in IBS-D patients. In total, 23 of 55 IBS-D patients and 15 of 28 HCs participated in the visceral sensitivity test. The first sensation threshold was negatively correlated with CDCA ( = -0.459, = 0.028) in IBS-D patients. Furthermore, the relative abundance of the family was significantly decreased in IBS-D patients ( < 0.001), and 12 genera were significantly lower in IBS-D patients than in HCs ( < 0.05), with 6 belonging to . Eleven of these genera were negatively correlated with primary BAs and positively correlated with secondary BAs in all subjects.
Conclusion: The altered metabolism of BAs in the gut of IBS-D patients was associated with diarrhea and visceral hypersensitivity and might be ascribed to dysbiosis, especially the reduction of genera in .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723672 | PMC |
http://dx.doi.org/10.3748/wjg.v26.i45.7153 | DOI Listing |
BMC Gastroenterol
December 2024
Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. Dr. Eneas C Aguiar 255, Sao Paulo-SP, 9117, Brazil.
Background: Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. Recently, two autoantibodies, anti-CdtB and anti-vinculin, were validated as post-infectious IBS (PI-IBS) markers, however there is limited evidence of its diagnostic role in IBD population.
Methods: Patients with more than 3 bowel movements/day and indication of colonoscopy were enrolled.
Food Sci Nutr
November 2024
Department of Laboratory Sciences, School of Paramedical Sciences Mashhad University of Medical Sciences Mashhad Iran.
Am J Gastroenterol
November 2024
Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium.
Background: Treatment with non-resorbable antibiotics is effective in diarrhea predominant irritable bowel syndrome (IBS-D). Multimatrix® (MMX®) formulations ensure targeted drug delivery to the mid-distal small bowel and colon - traditionally considered the origin of IBS symptoms.
Aim: To assess the efficacy of Rifamycin SV-MMX for the treatment of IBS-D.
Neuropsychiatr Dis Treat
November 2024
Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, 610044, People's Republic of China.
Background: To identify irritable bowel syndrome with diarrhea (IBS-D) combined with anxiety and/or depression through a psychological screening tool and to further explore the relationships between patients with comorbidities and gut microbiota.
Methods: The GAD-7, SAS, PHQ-9 and SDS were administered to evaluate anxiety and depression. Faeces were subsequently collected from 44 patients with emotional disorders (IBS-EDs), 22 patients without emotional disorders (IBS-nEDs) and 18 healthy controls (HCs) via 16S rRNA sequencing, depending on the participants' wishes.
Medicine (Baltimore)
November 2024
Research Institute of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, China.
Background: Presently, a diverse range of Western medical interventions are accessible for the management of irritable bowel syndrome with diarrhea (IBS-D) concomitant with comorbid anxiety and depression. However, the concomitant adverse effects have also surfaced, exerting strain on healthcare resources and the socio-economic structure. In recent times, the benefits of acupuncture in the management of IBS-D with coexisting anxiety and depression have become progressively evident.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!